At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?

Still feeling the reverberations of data released in Barcelona in September, this year's TCT meeting saw session after session on the risks of stent thrombosis from drug-eluting stents. While the data was clear--there is some risk, but not a lot--what to do about it was less clear. And the whole debate raises more questions than answers, for both interventionalists and cardiovascular device companies.

The bomb over drug-eluting stent (DES) safety that went off in Barcelona last September at the World Cardiology Congress was still reverberating six weeks later at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington. At the WCC meeting, researchers presented data on the incidence of thrombosis, particularly sub-acute, between 1 and 12 months, and late stent thrombosis, more than 12 months, compared with the risk in bare metal stents (BMS), and the headlines blared the scary findings: "Are DES Killing Patients?" read one. Also see "Renewed DES Safety Debate Creates Second Generation Mover Advantage " - In Vivo, 1 October, 2006.

Six weeks later at TCT, interventionalists and researchers, including some who had presented in Barcelona, sought eagerly to put what...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.